TY - JOUR
T1 - Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis
T2 - A 52-Week International, Multicenter Retrospective Cohort Study
AU - Torres, Tiago
AU - Yeung, Jensen
AU - Prajapati, Vimal H.
AU - Ribero, Simone
AU - Balato, Anna
AU - Marzano, Angelo Valerio
AU - Cruz, Maria João
AU - Paiva Lopes, Maria João
AU - Lazaridou, Elizabeth
AU - Carrascosa, Jose Manuel
AU - Alvarenga, José Miguel
AU - Farinha, Pedro
AU - Duarte, Bruno
AU - Munera-Campos, Monica
AU - Sood, Siddhartha
AU - Rankin, Brian D.
AU - Ortoncelli, Michela
AU - Caccavale, Stefano
AU - Ferrucci, Silvia Mariel
AU - Pires Rosa, Gilberto
AU - Daponte, Athina Ioanna
AU - Silvi, Gianmarco
AU - Peris, Ketty
AU - Gori, Niccolò
AU - Prignano, Francesca
AU - Kolios, Antonio
AU - Herranz, Pedro
AU - Gregoriou, Stamatios
AU - Rompoti, Natalia
AU - Gkalpakiotis, Spyridon
AU - Chiricozzi, Andrea
PY - 2025/8
Y1 - 2025/8
N2 - Introduction: Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial. In this international, multicenter, retrospective, comparative study we aimed to evaluate the 52-week effectiveness, safety, and tolerability of dupilumab, tralokinumab, and upadacitinib in patients with AD aged ≥ 12 years. Methods: Effectiveness was assessed at weeks 16, 24, and 52 using Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (NRS) scores. Safety was measured via adverse events (AEs). Results: A total of 1286 treatment courses were included: 62.5% received dupilumab, 24.3% received upadacitinib, and 13.1% received tralokinumab. Upadacitinib demonstrated higher effectiveness than dupilumab and tralokinumab across all time points and most evaluated outcomes both on the overall population and the biologic-/JAKi-naïve population, including stringent treatment targets such as EASI 90 response and combined EASI 90 + itch NRS 0/1 response. While upadacitinib demonstrated superior effectiveness, it was associated with a higher incidence of AEs, both leading to and not leading to treatment discontinuation, including thromboembolic events, lipid abnormalities, and hematologic abnormalities. In contrast, conjunctivitis was the most frequently observed AE among patients receiving biologics. Conclusion: This study provides a comprehensive real-world comparison of dupilumab, tralokinumab, and upadacitinib in AD, highlighting upadacitinib’s superior effectiveness in achieving stringent treatment targets, both in the short and long term, but also a higher incidence of AEs. However, the considerable heterogeneity of the study population, an inherent limitation of real-world studies, must be acknowledged when interpreting these findings.
AB - Introduction: Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial. In this international, multicenter, retrospective, comparative study we aimed to evaluate the 52-week effectiveness, safety, and tolerability of dupilumab, tralokinumab, and upadacitinib in patients with AD aged ≥ 12 years. Methods: Effectiveness was assessed at weeks 16, 24, and 52 using Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (NRS) scores. Safety was measured via adverse events (AEs). Results: A total of 1286 treatment courses were included: 62.5% received dupilumab, 24.3% received upadacitinib, and 13.1% received tralokinumab. Upadacitinib demonstrated higher effectiveness than dupilumab and tralokinumab across all time points and most evaluated outcomes both on the overall population and the biologic-/JAKi-naïve population, including stringent treatment targets such as EASI 90 response and combined EASI 90 + itch NRS 0/1 response. While upadacitinib demonstrated superior effectiveness, it was associated with a higher incidence of AEs, both leading to and not leading to treatment discontinuation, including thromboembolic events, lipid abnormalities, and hematologic abnormalities. In contrast, conjunctivitis was the most frequently observed AE among patients receiving biologics. Conclusion: This study provides a comprehensive real-world comparison of dupilumab, tralokinumab, and upadacitinib in AD, highlighting upadacitinib’s superior effectiveness in achieving stringent treatment targets, both in the short and long term, but also a higher incidence of AEs. However, the considerable heterogeneity of the study population, an inherent limitation of real-world studies, must be acknowledged when interpreting these findings.
KW - Atopic dermatitis
KW - Dupilumab
KW - Effectiveness
KW - Safety
KW - Tralokinumab
KW - Upadacitinib
UR - http://www.scopus.com/inward/record.url?scp=105007069907&partnerID=8YFLogxK
U2 - 10.1007/s13555-025-01453-8
DO - 10.1007/s13555-025-01453-8
M3 - Article
AN - SCOPUS:105007069907
SN - 2193-8210
VL - 15
SP - 2295
EP - 2305
JO - Dermatology and Therapy
JF - Dermatology and Therapy
IS - 8
ER -